Researchers discover severe side effects of approved multiple sclerosis medication

January 18, 2017 by Julia Weiler, Ruhr-Universitaet-Bochum

The multiple sclerosis (MS) therapy alemtuzumab can trigger severe, unpredictable side effects. This was the finding by a team led by Prof Dr Aiden Haghikia and Prof Dr Ralf Gold from the Department of Neurology of the Ruhr-Universität Bochum at St. Josef's Hospital. In the journal Lancet Neurology, the scientists report on two patients for whom the infusion of alemtuzumab significantly worsened symptoms. The team also describes a treatment that successfully curbed the harmful side effects.

"This therapeutic algorithm could help MS around the world who develop similar under ," says Haghikia.

How alemtuzumab works

Alemtuzumab is a therapeutic antibody that docks to the protein CD52 on the surface of certain immunocytes, mainly T and B lymphocytes, leading to the depletion of almost all lymphocytes.

It was already known from the approval studies that a quarter of the treated patients display mostly minor side effects, called secondary autoimmune processes: immunocytes turn against cells produced naturally in the body, predominantly in the thyroid gland; but the kidneys and platelets can also be affected.

A new inflammation mode

The two patients described in the Lancet Neurology study received alemtuzumab because they had highly active MS, i.e. despite numerous previous treatments, they suffered from severe illness relapses with inflammation in the central nervous system. Six months after the treatment, these symptoms had worsened significantly. Using MRI, the researchers discovered a kind of new inflammation mode: they found vast areas in the brain with numerous ring enhancing lesion. The patients had not displayed this pattern in their previous medical history.

It is currently unclear whether the observed adverse events represent increased MS activity or an independent secondary autoimmune process.

Side effects curbed

In both cases, the neurologists were able to curb the side effects, and the observed ring-shaped deposits in the brain receded. Even a year after the treatment, the patients were still in a stable condition. Besides a blood plasma exchange, they treated both with the antibody rituximab that is directed against B lymphocytes. The researchers suspect that precisely these immunocytes were responsible for the observed side effect.

The authors propose that the measures they applied could also benefit other patients who develop similar adverse events under alemtuzumab.

Multiple sclerosis

Multiple sclerosis is the most common neurological condition in young adults. It is characterised by chronic inflammation in the central nervous system. The body's immune system attacks the insulating layer around the nerve fibres, the so-called myelin, and thus permanently damages the cellular protuberances. There are now ten different classes of medications that are specially approved for MS treatment and were found to be effective in major studies. These also include alemtuzumab, labled as Lemtrada.

Explore further: Multiple sclerosis drug may reverse some physical disability

More information: Aiden Haghikia et al, Severe B-cell-mediated CNS disease secondary to alemtuzumab therapy, The Lancet Neurology (2017). DOI: 10.1016/S1474-4422(16)30382-9

Related Stories

Multiple sclerosis drug may reverse some physical disability

October 12, 2016
A drug used to treat multiple sclerosis (MS), alemtuzumab, was found to reverse some of the physical disability caused by the disease, according to new research published in the October 12, 2016, online issue of Neurology, ...

Drug approved for treatment of multiple sclerosis

September 18, 2013
A transformational new treatment for multiple sclerosis (MS) - the result of over three decades of research in Cambridge - was approved today by the EU agency responsible for regulating new drugs.

New MS drug proves effective where others have failed

October 31, 2012
A drug which 'reboots' a person's immune system has been shown to be an effective treatment for multiple sclerosis (MS) patients who have already failed to respond to the first drug with which they were treated (a 'first-line' ...

New treatment for Multiple Sclerosis: Cambridge University translates research at the bench into a drug at the bedside

November 15, 2011
The culmination of three decades of research in Cambridge has resulted in the exciting prospect of a new transformational treatment for multiple sclerosis.

NICE approves MS drug developed by University of Cambridge researchers

May 28, 2014
A new drug based on decades of research at the University of Cambridge has today been approved by the National Institute of Health and Care Excellence (NICE) for use in people with relapsing-remitting multiple sclerosis. ...

Recommended for you

Researchers identify source of molecule linked to nasal polyps, asthma attacks

May 23, 2018
A new discovery about how the immune system responds to common sinus infections and asthma could explain why patients develop these issues in the first place and ultimately may lead to improved targeted therapies. Researchers ...

Study demonstrates new treatment for severe asthma

May 22, 2018
Researchers from McMaster University and the Firestone Institute for Respiratory Health at St. Joseph's Healthcare Hamilton, together with colleagues at other partnering institutions, have developed a new method to treat ...

Eczema drug effective against severe asthma

May 21, 2018
Two new studies of patients with difficult-to-control asthma show that the eczema drug dupilumab alleviates asthma symptoms and improves patients' ability to breathe better than standard therapies. Dupilumab, an injectable ...

Neuron guidance factor found to play a key role in immune cell function

May 21, 2018
Macrophages are white blood cells involved in a variety of biological functions, from destroying infectious pathogens to repairing damaged tissue. To carry out their different roles, macrophages must first be activated and ...

Immune cells hold promise in slowing down ALS

May 21, 2018
Recent research from Houston Methodist Hospital showed that a new immunotherapy was safe for patients with ALS and also revealed surprising results that could bring hope to patients who have this relentlessly progressive ...

First clues to the causes of multiple sclerosis

May 16, 2018
Multiple sclerosis, which affects one in 1,000 people, is frequently characterised by relapses associated with variable functional impairments including among others vision problems, impairment of locomotor functions or difficulties ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.